DSP107
- Generic Name
- DSP107
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain of SIRPα and 4-1BBL.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Kahr Medical
- Target Recruit Count
- 36
- Registration Number
- NCT04937166
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas, United States
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Kahr Medical
- Target Recruit Count
- 125
- Registration Number
- NCT04440735
- Locations
- 🇺🇸
Moores Cancer Center, UCSD, La Jolla, California, United States
🇺🇸University of Colorado Hospital, Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
🇺🇸Florida Cancer Specialists, Lake Mary, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath